The vesicular monoamine transporter-2 is the sole transporter responsible for sequestration of monoamines, including dopamine (DA), into synaptic vesicles. Previous studies demonstrate that agents that inhibit DA transporter function, such as cocaine, increase vesicular [H-3]DA uptake and binding of the ligand [H-3]dihydrotetrabenazine ([H-3]DHTBZ), as assessed in vesicles prepared from treated rats. The present studies examine the role of DA receptors in these cocaine-induced effects. Results demonstrate that administration of the D-2 DA receptor antagonist, eticlopride, but not the D-1 DA receptor antagonist, SCH23390, inhibited these cocaine-induced increases. Similar to the effects of cocaine, treatment with the D-2 agonist, quinpirole, increased both vesicular [H-3]DA uptake and [H-3]DHTBZ binding. In contrast, administration of the D-1 agonist, SKF81297, was without effect on vesicular [H-3]DA uptake or [H-3]DHTBZ binding. Finally, coadministration of quinpirole and cocaine did not further increase vesicular [H-3]DA uptake or [H-3]DHTBZ binding when compared with treatment with either agent alone. These data suggest that cocaine-induced increases in vesicular DA uptake and DHTBZ binding are mediated by a D-2 receptor-mediated pathway. Furthermore, results indicate that D-2 receptor activation, per se, is sufficient to increase vesicular DA uptake.